iTeos Therapeutics Ownership | Who Owns iTeos Therapeutics?

Overview Forecast RevenueFinancials Chart

iTeos Therapeutics Ownership Summary

iTeos Therapeutics is owned by 100.82% institutional investors, 0.70% insiders. Blackrock is the largest institutional shareholder, holding 10.41% of ITOS shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.34% of its assets in iTeos Therapeutics shares.

ITOS Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	iTeos Therapeutics	100.82%	0.70%	-1.52%
Sector	Healthcare Stocks	47.31%	8.01%	44.69%
Industry	Biotech Stocks	45.43%	7.81%	46.75%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Blackrock	3.73M	10.41%	$55.37M
Ra capital management	3.52M	9.81%	$52.20M
Ecor1 capital	3.25M	9.07%	$48.23M
Boxer capital	2.95M	8.22%	$43.73M
Mpm asset management	2.74M	7.64%	$40.64M
Vanguard group	2.05M	5.72%	$30.42M
Vestal point capital, lp	1.75M	4.88%	$25.97M
Bioimpact capital	1.75M	4.87%	$25.91M
683 capital management	1.11M	3.11%	$16.55M
Morgan stanley	1.09M	3.04%	$16.17M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Mpm asset management	2.74M	22.32%	$40.64M
Bioimpact capital	1.75M	4.03%	$25.91M
Boxer capital	2.95M	2.30%	$43.73M
Saturn v capital management	367.43K	2.06%	$5.45M
Vestal point capital, lp	1.75M	1.94%	$25.97M
Ecor1 capital	3.25M	1.48%	$48.23M
683 capital management	1.11M	1.25%	$16.55M
K2 principal fund	257.08K	0.71%	$3.82M
Ra capital management	3.52M	0.69%	$52.20M
Sectoral asset management	96.97K	0.58%	$1.44M

Top Buyers

Holder	Shares	% Assets	Change
Vestal point capital, lp	1.75M	1.94%	1.75M
Ecor1 capital	3.25M	1.48%	1.25M
Boxer capital	2.95M	2.30%	1.14M
Vanguard group	2.05M	0.00%	549.40K
Candriam s.c.a.	509.30K	0.05%	509.30K

Top Sellers

Holder	Shares	% Assets	Change
Braidwell lp	-	-	-1.16M
Ra capital management	3.52M	0.69%	-900.00K
Deerfield management company, l.p. (series c)	-	-	-723.00K
Millennium management	241.31K	0.00%	-641.68K
Morgan stanley	1.09M	0.00%	-543.06K

New Positions

Holder	Shares	% Assets	Change	Value
Vestal point capital, lp	1.75M	1.94%	1.75M	$25.97M
Candriam s.c.a.	509.30K	0.05%	509.30K	$7.56M
Clearline capital lp	156.89K	0.06%	156.89K	$2.33M
Adar1 capital management	60.00K	0.17%	60.00K	$890.40K
Rafferty asset management	35.98K	0.00%	35.98K	$534.02K

Sold Out

Holder	Change
Nelson, van denburg & campbell wealth management group	-5.00
Avion wealth	-103.00
Pacer advisors	-205.00
Point72 (difc)	-1.23K
Metropolitan life insurance co/ny	-1.36K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2024	138	1.47%	36,138,016	4.70%	100	1.09%	73	37.74%	40	-25.93%
Mar 31, 2024	136	-0.73%	34,517,358	-1.12%	96	1.01%	53	-29.33%	54	35.00%
Dec 31, 2023	137	-8.05%	34,908,053	-1.63%	97	0.99%	75	2.74%	40	-14.89%
Sep 30, 2023	149	0.68%	35,487,057	2.07%	99	1.05%	73	-1.35%	47	-
Jun 30, 2023	148	-3.90%	34,766,079	-3.38%	97	0.96%	74	7.25%	47	-16.07%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Total Stock Mkt Idx Inv	855.64K	2.34%	-413.20K
iShares Russell 2000 ETF	671.53K	1.84%	-1.51K
SPDR® S&P Biotech ETF	549.67K	1.51%	6.07K
Candriam Eqs L Biotech C USD Cap	535.59K	1.47%	-
Vanguard Institutional Extnd Mkt Idx Tr	426.13K	1.17%	7.71K
BlackRock Advantage Small Cap Core Instl	423.18K	1.16%	17.94K
Fidelity Small Cap Index	264.21K	0.72%	-7.04K
iShares Russell 2000 Value ETF	255.74K	0.70%	-
Belfius Equities Cure C Cap	233.62K	0.64%	-
Candriam Global Equities Oncology	233.62K	0.64%	148.62K

Recent Insider Transactions

Date	Name	Role	Activity	Value
May 10, 2024	RA CAPITAL MANAGEMENT, L.P.	Former 10% Owner	Buy	$5.71K
Oct 12, 2023	Gall Matthew	Chief Financial Officer	Buy	$41.85K
Aug 23, 2023	Boxer Capital, LLC	-	Sell	$1.49M
Aug 23, 2023	Boxer Capital, LLC	-	Sell	$3.71M
Aug 23, 2023	Boxer Capital, LLC	-	Sell	$494.46K

Insider Transactions Trends

Date	Buy	Sell
2024 Q3	-	-
2024 Q2	1	-
2024 Q1	-	-
2023 Q4	1	-
2023 Q3	-	3

ITOS Ownership FAQ

Who Owns iTeos Therapeutics?

iTeos Therapeutics shareholders are primarily institutional investors at 100.82%, followed by 0.70% insiders and -1.52% retail investors. The average institutional ownership in iTeos Therapeutics's industry, Biotech Stocks , is 45.43%, which iTeos Therapeutics exceeds.

Who owns the most shares of iTeos Therapeutics?

iTeos Therapeutics’s largest shareholders are Blackrock (3.73M shares, 10.41%), Ra capital management (3.52M shares, 9.81%), and Ecor1 capital (3.25M shares, 9.07%). Together, they hold 29.29% of iTeos Therapeutics’s total shares outstanding.

Does Blackrock own iTeos Therapeutics?

Yes, BlackRock owns 10.41% of iTeos Therapeutics, totaling 3.73M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 55.37M$. In the last quarter, BlackRock decreased its holdings by -384K shares, a -9.33% change.

Who is iTeos Therapeutics’s biggest shareholder by percentage of total assets invested?

Mpm asset management is iTeos Therapeutics’s biggest shareholder by percentage of total assets invested, with 22.32% of its assets in 2.74M iTeos Therapeutics shares, valued at 40.64M$.

Who is the top mutual fund holder of iTeos Therapeutics shares?

Vanguard Total Stock Mkt Idx Inv is the top mutual fund holder of iTeos Therapeutics shares, with 2.34% of its total shares outstanding invested in 855.64K iTeos Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools